Clinuvel Pharmaceuticals Limited (CUVL)
Develops skin-protective medicines using melanocortin technology for rare genetic disorders and UV damage
$7.01+0.00%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-11.3%
The outlook
CUVL is trading near the lower third of its 52-week range, sitting flat today. Analyst coverage appears limited, and the stock shows mixed positioning relative to its moving averages. The trailing P/E of 15.6 sits at a moderate valuation level.
What’s behind the score
Price trendMixed vs its moving averages
52-week range34% of the way from its 52-week low to high
Market cap
$353.5M
52-wk high
$9.00
52-wk low
$5.98
50-day avg
$6.92
200-day avg
$7.36
Trailing P/E
15.6